Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | TNO155 in advanced solid tumors

Irene Brana, MD, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, discusses the updated results of a Phase I study (NCT03114319), investigating the safety and efficacy of the SHP2 inhibitor TNO155 in advanced solid tumors. TNO155 was found to sustainably inhibit SHP2 in advanced solid tumors and was generally well tolerated by patients. The study is now focussed on the efficacy of TNO155 as a single agent in KRAS G12 mutants and BRAF-NRAS melanoma, as well as its efficacy in combination with the EGFR inhibitor nazartinib. Further trials are investigating the efficacy of TNO155 in combination with other therapeutics, such as the anti-PD1-inhibitor spartalizumab and the ERK inhibitor LTT462 (NCT04294160). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.